Browse by author
Lookup NU author(s): Professor Steve Wedge
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
There has been significant investment in developing novel therapies to target solid tumour vasculature. Different technical approaches have been utilized with the aim of inhibiting tumour angiogenesis or compromising the function or stability of pre-existing tumour blood vessels. The vascular endothelial growth factor (VEGF) signalling axis remains the most widely studied, with biological and small-molecule therapeutics now registered for clinical use. However, despite these successes, the activity of these agents is not as widespread as was first postulated. The present review discusses the clinical successes of the VEGF inhibitors, the factors that may limit their utility, and the potential opportunities to maximize benefit from treatment with these agents in the future.
Author(s): Smith NR, Wedge SR, Pommier A, Barry ST
Publication type: Article
Publication status: Published
Journal: Biochemical Society Transactions
Print publication date: 01/12/2014
Acceptance date: 23/09/2014
ISSN (print): 0300-5127
ISSN (electronic): 1470-8752
Publisher: Portland Press Ltd
Altmetrics provided by Altmetric